BioSpace News Archive

AGEN1223 is a novel bi-specific designed to selectively deplete regulatory T cells in the tumor microenvironment

James P. Allison, Ph.D., a 2018 Nobel Prize recipient in Physiology or Medicine for his discovery of cancer therapy by inhibition of negative immune regulation, and Padmanee Sharma, M.D., Ph.D., a scientific leader in oncology, specializing in renal, bladder and prostate cancer, have joined the company’s Advisory Board.

Potential First-in-Class Therapy for Chronic Spinal Cord Injury

Puts Spotlight on Decades of Enzo’s False Promises and Underperformance While its Board and Management Continue to Receive Excessive Compensation at Shareholders’ Expense

Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the appointment of James P. Panek to its Board of Directors

Generex Biotechnology Corporation (OTCQB:GNBT) is pleased to announce that the company has been selected as the featured organization to present at the 2020 Wall Street Conference and Retreat to be held in West Palm Beach, FL from February 19 to 20.

Stericycle Communication Solutions, an industry leader in patient engagement technology and solutions and a Strategic Alliance Partner of Yext, Inc. (NYSE: YEXT), the Search Experience Cloud Company, today announced the integration of its InQuicker™ online scheduling solution directly into the Yext platform

PharmaJet, the maker of innovative, needle-free injection technology, announced that the results of the Invectys Phase I clinical trial of its therapeutic cancer vaccine, INVAC-1, using the PharmaJet needle-free injection system, were recently published.

RxGen, a translational research company ensuring definitive, actionable preclinical outcomes through the use of predictive, validated disease models, today announced it is rebranding as Virscio (vir’sio) to reflect substantial expansion of capabilities since inception and growth into a leading nonhuman primate preclinical research organization.

Sienna Senior Living Inc. (“Sienna” or the “Company”) (TSX: SIA) announced that it will report its 2019 fourth quarter results after market close on Wednesday, February 19, 2020. Lois Cormack, President and Chief Executive Officer, and Nitin Jain, Chief Financial Officer and Chief Investment Officer, will host a conference call for the investment community the following day, Thursday, February 20, 2020 at 9:30 a.m. (ET).